12:00 AM
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dexanabinol: Phase I started

e-Therapeutics began a dose-escalation, U.K. Phase I trial to evaluate IV ETS2101 administered on days 1, 8 and 15 of a 21-day cycle in up to 45 patients. In...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >